- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05677282
Eenmalige dosis antibioticabehandeling van acute waterige diarree, rifaximine versus azithromycine, met loperamide-adjunct (TrEAT_TD2)
Een gerandomiseerde, gecontroleerde studie ter evaluatie van een enkele dosis rifaximin versus azithromycine met loperamide-adjunct voor de behandeling van acute waterige diarree
The purpose of this study is to compare a single dose of rifaximin with loperamide to the current standard approach of single dose azithromycin with loperamide for the treatment of acute watery traveler's diarrhea (TD).
The study requires 1) taking a single dose antibiotic plus loperamide to treat TD, 2) providing blood and stool samples at different time points to evaluate infection and immune responses, 3) completing a daily symptom diary following treatment, 4) being seen by the study doctor to monitor illness and recovery, and 5) completing a brief electronic questionnaire at 3 months.
Participants will be randomly assigned to one of the two treatment groups. The two groups are 1) rifaximin 550 mg as a single dose with loperamide or 2) azithromycin 500 mg as a single dose with loperamide. Both groups will take the antibiotic dose with 4 mg of loperamide. Participants are provided additional loperamide with instructions that they may take a 2 mg after continued diarrheal stools up to a maximum of 8 mg per day as needed.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Djibouti, Djibouti
- Camp Lemonnier Djibouti
-
-
-
-
Nueva Ecija
-
Santa Rosa, Nueva Ecija, Filippijnen
- Fort Magsaysay & Camp Aguinaldo
-
-
-
-
-
Comayagua, Honduras
- JTF-Bravo, Soto Cano AB
-
-
-
-
-
Nanyuki, Kenia
- British Army Training Site UK
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Active duty military, 18-60 years old
- Presence of acute watery diarrhea (3 or more loose/liquid stools in 24 hours or 2 loose/liquid stools in 24 hours and associated symptoms such as nausea, vomiting, abdominal cramps or tenesmus) lasting <96 hours in duration that impacts function in activities and/or performance of primary duties. Refer to recruitment decision tree below.
- Eligible for ambulatory management. (Note: Ambulatory management in this study means that the patient can be treated on an outpatient basis to include up to 23 hours of medical observation and IV therapies.)
- Able to comply with follow-up procedures.
- Will remain in country for at least 7 days or an assurance that follow-up can be arranged elsewhere.
Exclusion Criteria:
- Allergy to rifamycins, macrolides, or loperamide (not including mild gastrointestinal upset).
- Antibiotic therapy in the 72 hours prior to presentation (excluding malaria prophylaxis with mefloquine, malarone, chloroquine/proguanil, tafenoquine, or doxycycline).
- Concomitant medications with known drug-drug interactions with any of the study drugs (includes theophylline, digoxin, warfarin, chloroquine and hydroxychloroquine).
- Current or history of liver disease or other serious health conditions based on review by study physician.
- Acute dysentery and/or febrile illness (temperature > 100.4°F [38.1°C]).
- Presence of symptoms >96 hours prior to initiating treatment.
- Use of >4 mg loperamide or use of any amount of loperamide for greater than 24 hours prior to enrollment. Prior use of bismuth subsalicylate or other anti-diarrheal, non-antibiotic therapy in the 48 hours prior to enrollment.
- Positive pregnancy test at presentation (unknown effects with rifaximin). All female participants will be administered a urine pregnancy test prior to enrollment.
- Previously screened or randomized in this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Rifaximin met loperamide
|
Rifaximin 550 mg as a single dose administered orally. 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool). |
|
Actieve vergelijker: Azitromycine mg met loperamide
|
4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool). Azithromycin 500 mg as a single dose administered orally. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Therapeutic Efficacy: Time to Last Unformed Stool (TLUS)
Tijdsspanne: Up to 1 week (up to 168 hours)
|
The primary efficacy endpoint is the time to last unformed stool (TLUS). TLUS is calculated from the time of antibiotic dose to last unformed stool meeting the pre-defined traveler's diarrhea definition. |
Up to 1 week (up to 168 hours)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Cure Rate
Tijdsspanne: 24, 48, and 72 hours
|
The clinical efficacy cure rate is the percentage of participants that met criteria for both diarrhea resolution and symptom resolution within the specified window, at 24, 48, and 72 hours following initial study treatment. To meet criteria for symptom resolution, there must be no traveler's diarrhea (TD) associated symptoms reported as moderate or greater and no impact on activities for last 24 hour period. |
24, 48, and 72 hours
|
|
Return to Normal Activities
Tijdsspanne: 24, 48, and 72 hours
|
The percentage of participants that reported activities were not impacted at the end of the specified window, at 24, 48, and 72 hours following initial study treatment. |
24, 48, and 72 hours
|
|
Number of Participants With Recurrence of Traveler's Diarrhea
Tijdsspanne: 7 days
|
Participants that experienced a recurrence of traveler's diarrhea after previously meeting criteria for clinical cure resolution. |
7 days
|
|
Number of Participants Requiring Rescue Treatment
Tijdsspanne: 3 days
|
The number of participants whose illness worsened or continued to impact functional capacity at the 72-hour time point requiring their treatment code to be broken so appropriate rescue treatment could be prescribed. |
3 days
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, gefuseerd ring
- Polycyclische verbindingen
- Piperidines
- Macrolides
- Lactonen
- Heterocyclische verbindingen, 4 of meer ringen
- Rifamycins
- Lactams, macrocyclisch
- Macrocyclische verbindingen
- Erytromycine
- Polyketiden
- Rifaximin
- Azitromycine
- Loperamide
Andere studie-ID-nummers
- IDCRP-115
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .